Quality of Life in Patients With Short Bowel Syndrome Treated Without and With Teduglutide - a Prospective Nested Matched Pair Analysis

Short Bowel Syndrome Clinical Trial

— MatchedQoL  

Official title:

Quality of Life in Patients With Short Bowel Syndrome Treated Without and With Teduglutide - a Prospective Nested Matched Pair Analysis

Clinical Trial Details — Status: Recruiting

Administrative data

• NCT number: NCT04733066
• Other study ID #: IIR-DE-002726
• Status: Recruiting
• Start date: September 1, 2020
• Est. completion date: September 2022

Study information

• Verified date: January 2021
• Source: Charite University, Berlin, Germany
• Contact: Elisabeth Blüthner, MD
• Phone: 004930450665209
• Email: elisabeth.bluethner[@]charite.de
• Is FDA regulated: No
• Study type: Observational

Clinical Trial Summary

The aim of this prospective longitudinal study is to compare the quality of life of short bowel patients prior to and on teduglutide treatment with a non-treated patient group in a matched-pair design.

Description:

Short bowel syndrome (SBS) is a malabsorptive disorder mostly caused by surgical interventions, which may result in chronic intestinal failure (cIF). The incidence is progressively increasing due to more aggressive surgical and medical approaches. Parenteral nutrition is still the mainstay of treatment for patients with irreversible cIF. New hormonal therapies hold promise by romoting mucosal growth and intestinal absorption and thereby leading to a consequent reduction in parenteral support and symptoms related to large stomal or faecal losses. Outside the typical primary endpoints of cost data, quality of life (QoL) is an important and yet underappreciated consideration of the effectiveness of targeted therapies. In the clinical STEPS trial, Jeppesen et al. have previously shown a significant improvement of the SBS-QoL total score after 24 week treatment with teduglutide longitudinally but could not identify a statistical significance to the placebo group. Accordingly, Chen and colleagues carried out a post hoc analysis of the afore mentioned clinical trial data based on 86 patients and could confirm the results auf Jeppesen et al. Taken together, these clinical trial data did not show a direct benefit of teduglutide treatment on QoL in these patients, while real life data on QoL changes are not available yet. During the release of teduglutide in Germany, the PNLiver trial (DRKS00010993) recruited chronic intestinal failure patients with parenteral nutrition from 2014 till 2019 to evaluate the capability of non-invasive liver function tests in cIF patients in a cross-sectional (n=90) and longitudinal study (n=20. All participants underwent study visits including clinical examination, dynamic liver function assessment, comprehensive blood tests, nutritional status assessment and quality of life assessment (Short Form 36 [SF-36] and SBS-QoL). Therefore, we have a comprehensive data set of a large monocentric cIF cohort prior to teduglutide treatment. Consequently, our unique QoL data from the PNLiver trail enables a followup assessment for an observation period above 24 weeks of patients who were in the meantime exposed to teduglutide in a real life setting. Nevertheless, QoL also tends to improve with longer duration on HPN. Therefore, we are aiming to extend the results with a pairwise matched control group from non teduglutide-treated PNLiver trail patients and collect follow-up data from this group accordingly.

Recruitment information / eligibility

• Status: Recruiting
• Enrollment: 40
• Est. completion date: September 2022
• Est. primary completion date: September 2021
• Accepts healthy volunteers: No
• Gender: All
• Age group: 18 Years and older

Eligibility

Inclusion Criteria:

• SBS-associated adult chronic IF with parenteral nutritional support

• previous inclusion in the PNLiver trial with existing SF-36 and SBSQoL data

• signed informed consent

Exclusion Criteria:

• teduglutide stop before study initiation

• refusal or withdrawal of consent

Related Conditions & MeSH terms

• Intestinal Failure
• Short Bowel Syndrome
• Syndrome

Intervention

Drug:
• Teduglutide
Intervention group consists of patients, who receive teduglutide within routine medical care

Locations

Country	Name	City	State
Germany	Charite University, Berlin, Germany	Berlin

Sponsors (2)

Lead Sponsor	Collaborator
Charite University, Berlin, Germany	Takeda

Country where clinical trial is conducted

Germany, 

References & Publications (4)

Blüthner E, Bednarsch J, Pape UF, Karber M, Maasberg S, Gerlach UA, Pascher A, Wiedenmann B, Pratschke J, Stockmann M. Advanced liver function assessment in patients with intestinal failure on long-term parenteral nutrition. Clin Nutr. 2020 Feb;39(2):540-547. doi: 10.1016/j.clnu.2019.02.039. Epub 2019 Mar 5. — View Citation

Blüthner E, Bednarsch J, Stockmann M, Karber M, Pevny S, Maasberg S, Gerlach UA, Pascher A, Wiedenmann B, Pratschke J, Pape UF. Determinants of Quality of Life in Patients With Intestinal Failure Receiving Long-Term Parenteral Nutrition Using the SF-36 Questionnaire: A German Single-Center Prospective Observational Study. JPEN J Parenter Enteral Nutr. 2020 Feb;44(2):291-300. doi: 10.1002/jpen.1531. Epub 2019 Mar 13. — View Citation

Chen K, Mu F, Xie J, Kelkar SS, Olivier C, Signorovitch J, Jeppesen PB. Impact of Teduglutide on Quality of Life Among Patients With Short Bowel Syndrome and Intestinal Failure. JPEN J Parenter Enteral Nutr. 2020 Jan;44(1):119-128. doi: 10.1002/jpen.1588. Epub 2019 Apr 21. — View Citation

Jeppesen PB, Pertkiewicz M, Forbes A, Pironi L, Gabe SM, Joly F, Messing B, Loth S, Youssef NN, Heinze H, Berghöfer P. Quality of life in patients with short bowel syndrome treated with the new glucagon-like peptide-2 analogue teduglutide--analyses from a randomised, placebo-controlled study. Clin Nutr. 2013 Oct;32(5):713-21. doi: 10.1016/j.clnu.2013.03.016. Epub 2013 Mar 28. — View Citation

Outcome

Type	Measure	Description	Time frame	Safety issue
Primary	changes in QoL data during teduglutide therapy	SBS-QoL, SF-36	through study completion, an average of 1 year
Primary	changes in QoL data of patients without teduglutide therapy	SBS-QoL, SF-36	through study completion, an average of 1 year
Primary	changes in QoL data of teduglutide treated patients compared to changes in pairwise matched controls	SBS-QoL, SF-36	through study completion, an average of 1 year
Secondary	BMI in kg/m^2	weight and height will be combined to report BMI in kg/m^2	through study completion, an average of 1 year
Secondary	Body cell mass in kg	measured by bioelectrical impedance analysis	through study completion, an average of 1 year
Secondary	citrulline levels		through study completion, an average of 1 year
Secondary	stool characteristics by bristol stool scale	seven types of stool from 1 (hard lumps) till 7 (watery)	through study completion, an average of 1 year
Secondary	parenteral support frequency		through study completion, an average of 1 year
Secondary	parenteral support volume		through study completion, an average of 1 year
Secondary	parenteral support calories		through study completion, an average of 1 year